Tags : HP-3000

Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for

Shots: Hisamitsu to receive upfront, milestone based on the regulatory approval and royalties on sales of product. Kyowa Kirin to get exclusive commercialization rights for Hisamitsu’s HP-3000, post marketing approval in Japan The focus of the agreement is to develop & commercialize therapies for Parkinson’s disease developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology […]Read More